

Automated chip-based extraction of HPV mRNA from cervical samples


T.Baier¹, T.Hansen-Hagge¹, R.Gransee¹, A.Crombé¹, S.Schmahl¹, C.Paulus¹, K.S. Drese¹, P.Grønn², L.Solli², I.M. Falang², A. Karlgard², F.Karlsen², C.Martin³, H.Keegan³, J.O'Leary³, L.Furberg⁴,
¹Institut für Mikrotechnik Mainz GmbH, Germany, ²NorChip AS, Klokkarstua, Norway,
³Coombe Women&Infants University Hospital, Dublin, Ireland, ⁴SINTEF ICT, Oslo, Norway



Contact: info@imm-mainz.de
 www.imm-mainz.de

- mRNA is a valuable bio-marker for detection of many common diseases.
- Presence of mRNA indicates biological activity of an agent and avoids false positive results if marker activity is required.
- mRNA detection allows early detection of cancer and other diseases.
- New biomarkers for various kinds of diseases emerge regularly.
- Cervical cancer is one of the most frequent types of cancer among women worldwide [1].
- Nearly all cases of this cancer are directly linked to previous infection with one or more types of human papilloma virus (HPV) [2].
- Early diagnosis of persistent HPV infections and subsequent treatment prevent onset of the disease.
- Against this background, a chip-based automated platform for the extraction of nucleic acids, including HPV mRNA from cervical smears as a model system, has been developed.
- The device accepts 3 ml of a suspension of fixated cervical smear cells in PreservCyt™.
- After insertion of sample and chip into the device the extraction procedure proceeds without further user interaction.

Experimental Set-up




Results: Successful Extraction and Validation

- The device has been successfully tested on various cell lines (HeLa, Ms751, CaSki) which express HPV mRNA.
- Device performance was validated by Nucleic Acid Sequence Based Amplification (NASBA) of the eluate, using the PreTect® HPV-Proofer kit (NorChip AS, Klokkarstua, Norway).
- A sensitivity study reveals amplifiable eluate down to 5 cells.
- First results show successful extraction for clinical cervical smear samples also.

Cell line / cell count	CaSki	MS751	HeLa
50.000	HPV16: positive	HPV45: positive	HPV18: positive
5.000	HPV16: positive	HPV45: positive	HPV18: positive
500	HPV16: positive	HPV45: positive	HPV18: positive
50	HPV16: positive	HPV45: positive	HPV18: positive
5	HPV16: positive	HPV45: negative	HPV18: positive

Results of sensitivity study of the sample preparation procedure. Samples of different cell lines containing from 5 to 50.000 cells were processed.



Sample NASBA amplification curve for HeLa cell lines showing fluorescence intensity vs. Time.

Conclusions and Outlook

- The sample preparation device presented here was developed within the project MicroActive. It is planned to integrate this device with a second automated instrument for on-chip parallel NASBA amplification and detection of several mRNA targets exemplified by different HPV types [3,4].
- This combined system may thus serve as a point of care system for the detection of gene expression directly in a physician's office, avoiding the often delayed analysis by a specialized laboratory.
- However, the device is not limited to cervical samples and opens the way for a wide range of similar sample preparation applications.
- With small modifications this system can be adapted to other fields of operation where it is desirable to analyse complex biological samples "in the field" and on a short timescale.
- This includes for example
 - > Foodstuff analysis / animal feed control
 - > Personalised Medicine, Point-Of-Care
 - > Forensics

References/Acknowledgements

[1] World Health Organization, "Fact sheet No. 297: Cancer", (2006)
 [2] J. M. M. Walboomers, et al., "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J. Pathol., 189, 1219, (1999).
 [3] A.Gulliksen, et al., "Parallel nanoliter detection of cancer markers using polymer microchips", Lab Chip, 2005, 5, 416-420
 [4] L. Furberg, et al., "RNA amplification chip with parallel microchannels and droplet positioning using capillary valves", Microsyst.Technol (2008) 14:673681.



This work was funded by the European commission under contract no. IST-NMT-CT-2005-017319.